CATX Stock Overview
Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$1.91 |
| 52 Week Low | US$0.20 |
| Beta | 1.44 |
| 1 Month Change | -23.76% |
| 3 Month Change | 30.19% |
| 1 Year Change | 153.21% |
| 3 Year Change | 55.21% |
| 5 Year Change | 246.56% |
| Change since IPO | 38.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CATX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | -0.4% | -0.6% |
| 1Y | 153.2% | 5.5% | 22.2% |
Return vs Industry: CATX exceeded the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: CATX exceeded the US Market which returned 22.3% over the past year.
Price Volatility
| CATX volatility | |
|---|---|
| CATX Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CATX's share price has been volatile over the past 3 months.
Volatility Over Time: CATX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 118 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Perspective Therapeutics, Inc. Fundamentals Summary
| CATX fundamental statistics | |
|---|---|
| Market cap | US$930.32m |
| Earnings (TTM) | -US$50.37m |
| Revenue (TTM) | US$1.53m |
609.6x
P/S Ratio-18.5x
P/E RatioIs CATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CATX income statement (TTM) | |
|---|---|
| Revenue | US$1.53m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.53m |
| Other Expenses | US$51.90m |
| Earnings | -US$50.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,300.98% |
| Debt/Equity Ratio | 3.4% |
How did CATX perform over the long term?
See historical performance and comparison